An estimated 200 million individuals worldwide have a thyroid disorder. Thyroid diseases affect seven times more women than men. People not diagnosed make up the majority of thyroid patients. There is a need to find novel and safe ways to change the underlying disease processes, rather than merely stop excess thyroid hormone production as in hyperthyroidism.
Metadichol® is a non emulsion of an extract of long-chain alcohols from food that is an inverse agonist of VDR (Vitamin D receptor), AHR (Aryl Hydrocarbon Receptor), and RORC (RAR Related Orphan Receptor C). The work presented here shows that Metadichol® is an inverse agonist of THRA (Thyroid Receptor Alpha) and THRB (Thyroid Receptor Beta). Case studies are presented that show how it can safely treat a multitude of thyroid related diseases. Network and pathway enrichment studies are presented that show how Metadichol® may be involved in action on multiple receptors and exerting its effects through multiple pathways. Metadicol® is the first of a breed of molecules that moves the goal post from the concept of ‘one drug, one target’ toward simultaneously targeting multiple targets, that can potentially lead to successful treatment of many diseases. Given the safety profile of Metadichol®, it would not only mitigate thyroid disease but prevent it and reduce the burden on healthcare budgets worldwide.
To read the full article click HERE.
Date of publication: 2019; Biology and Medicine
Author information: Raghavan PR (1)
(1) Nanorx Inc, Chappaqua, New York, USA